



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Onychomycosis

Page:

1 of 2

Effective Date: 3/4/2024

Last Review Date: 01/2024

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for onychomycosis under the patient's prescription drug benefit.

### Description:

#### Jublia

Jublia topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

#### Kerydin

Kerydin topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

### Applicable Drug List:

Jublia  
Kerydin

### Policy/Guideline:

**The requested drug will be covered with prior authorization when the following criteria are met:**

- The requested drug is being prescribed for onychomycosis of the toenail(s) due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*

**AND**

- The patient's diagnosis has been confirmed with a fungal diagnostic test (for example, potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)

**AND**

- The patient had a trial and failure, or there was a contraindication, with two formulary antifungal agents (for example, itraconazole, oral terbinafine, or ciclopirox)

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Onychomycosis

Page:

2 of 2

Effective Date: 3/4/2024

Last Review Date: 01/2024

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

### References:

1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; March 2022.
2. Kerydin [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; August 2018.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed August 7, 2023.
4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/07/2023).
5. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. American Academy of Family Physicians. 2021;104:359-368.
6. Centers for Disease Control (CDC) and Prevention. Fungal Nail infections. Available at: <https://www.cdc.gov/fungal/nail-infections.html>. Accessed August 7, 2023.